NANO.PA - Nanobiotix S.A.
Nanobiotix S.A.
60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 102
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, Pres of the Exec. Board & CEO | 635,14k | S.O. | 1973 |
| Mr. Bart Van Rhijn | CFO & Member of Exec. Board | 563,44k | S.O. | 1973 |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Exec. Board | 309,75k | S.O. | 1974 |
| Mr. Earl J. Bergey Ph.d. | Co-Founder | S.O. | S.O. | 1955 |
| Mr. Alain Dostie | Chief Operating Officer | S.O. | S.O. | S.O. |
| Ms. Kathryn M. McNeil | Sr. VP of Investor Relations | S.O. | S.O. | 1975 |
| Mr. Brandon Owens | VP of Strategic Marketing & Corp. Communication | S.O. | S.O. | S.O. |
| Mr. Patrick Tricoli M.B.A., Pharm.D. | Global Head of Bus. Devel. | S.O. | S.O. | S.O. |
| Ms. Margaret Galluzzi | VP & Global Head of Clinical Operations | S.O. | S.O. | S.O. |
| Mr. Ventzislav Vassilev M.D. | VP & Global Head of Safety Vigilance | S.O. | S.O. | S.O. |
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Nanobiotix S.A. en date du 1 juin 2023 est 9. Les scores principaux sont Audit : 6; Société : 7; Droits des actionnaires : 7; Compensation : 10.
